En un párrafo
Mammoth searches for and engineers unusually small CRISPR proteins. Size is the point: the standard delivery vehicle for in vivo therapy has a strict weight limit, and a smaller editor leaves room for everything else that has to travel with it. The same proteins also power rapid diagnostic tests.
Mammoth Biosciences was founded in 2017 by Jennifer Doudna, Trevor Martin, Janice Chen and Lucas Harrington. It develops ultracompact CRISPR systems including NanoCas for in vivo editing where AAV packaging limits bind, and CRISPR-based diagnostics derived from collateral cleavage activity.
Sources
- Mammoth Biosciences
Mammoth Biosciences ↗
No es asesoramiento de inversión
Este perfil es información educativa recopilada a partir de comunicaciones públicas. No es una recomendación de comprar, vender o mantener ningún valor, ni una opinión sobre las perspectivas de la empresa. La biotecnología es altamente especulativa y la mayoría de los programas clínicos fracasan.
Avisos legales completos →